Electrocardiographic findings and cardiac safety of hydroxychloroquine+azithromycin in hospitalized patients with COVID-19

Basit Öğe Kaydı
dc.authoridBEKLER, OZKAN/0000-0002-0031-6457
dc.contributor.authorAkkus, Oguz
dc.contributor.authorBal, Tayibe
dc.contributor.authorYagoobi, Hasibullah
dc.contributor.authorBekler, Ozkan
dc.contributor.authorAkkus, Gamze
dc.contributor.authorCabalak, Mehmet
dc.date.accessioned2024-09-18T20:02:38Z
dc.date.available2024-09-18T20:02:38Z
dc.date.issued2021
dc.departmentHatay Mustafa Kemal Ãœniversitesien_US
dc.description.abstractPurpose: The aim of this study was to determine the novel arrhythmia markers (Tpe, cTpe, cTpe/cQT) in addition to standard evaluation of 12-derived electrocardiography (ECG) and effects of therapy in patients with COVID-19. Materials and Methods: We evaluated 12-derived ECG in 51 patients with COVID-19 at the pre-treatment stage and on the 2nd and 5th days of the treatment, retrospectively. Patients were treated by either hydroxychloroquine (HCQ) + azithromycin or HCQ alone. Severe COVID-19 patients were defined with the presence of clinical signs and symptoms of pneumonia plus SpO2<90%, or respiratory rate > 30 breathe/minute. Results: While 68.6% of patients received HCQ + azithromycin combination therapy, 31.4% of patients received HCQ monotherapy. On the 2nd day of the treatment, heart rate was the only statistically significant variable either on the treatment of HCQ + azithromycin or HCQ alone. On the 5th day of treatment, in addition to the heart rate, Tpe and cTpe levels were also statistically significant among the whole treatment regimens. Although Tpe statistically significantly increased in both treatment strategies during treatment, increasing relative Tpe ratios were similar between both of the treatment strategies. Conclusion: The results of our study suggests that those off-label drugs (HCQ/azithromycin) have an acceptable cardiac safety profile in COVID-19 disease during short hospitalization.en_US
dc.identifier.doi10.17826/cumj.856174
dc.identifier.endpage698en_US
dc.identifier.issn2602-3032
dc.identifier.issn2602-3040
dc.identifier.issue2en_US
dc.identifier.startpage691en_US
dc.identifier.urihttps://doi.org/10.17826/cumj.856174
dc.identifier.urihttps://hdl.handle.net/20.500.12483/7928
dc.identifier.volume46en_US
dc.identifier.wosWOS:000694865200035en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherCukurova Univ, Fac Medicineen_US
dc.relation.ispartofCukurova Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectArrhythmiaen_US
dc.subjectcorrected QTen_US
dc.subjectCOVID-19en_US
dc.subjectTpeak- Tend intervalen_US
dc.titleElectrocardiographic findings and cardiac safety of hydroxychloroquine+azithromycin in hospitalized patients with COVID-19en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
Ä°sim:
7928.pdf
Boyut:
508.1 KB
Biçim:
Adobe Portable Document Format
Ä°ndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu